← Leaderboards
Csaba Szabo
Inotek Pharmaceuticals Corporation
$15,264,870
Attributed
$16,247,255
Total exposure
19
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$16,247,255 · 19
By mechanism
R01$7,503,204 · 5
R44$6,307,778 · 5
R21$1,150,527 · 3
R43$649,083 · 3
R41$300,000 · 1
R29$205,545 · 1
Top collaborators
- Mark R Hellmich5 shared
- Tracy E Toliver-Kinsky2 shared
Most similar at Inotek Pharmaceuticals Corporation
Same institution · by research overlap
- Fangming Zuo$1,288,390
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseBioenergeticsMitochondriaProductionPentosyltransferaseBaseEnzymesApoptosisLaboratory RatCellsInhibitor/AntagonistOxidative StressHydrogen SulfideMediatingIn VivoEnzyme ActivityDrug Screening /EvaluationIn VitroGasesElectron TransportBiologicalDrug Design /Synthesis /ProductionGenerationsBlood Vessels
Grant awards (47)
Role of Hydrogen Sulfide in Colorectal Tumors$312,124
R01 · FY2018 · CA · contact PI
Inhibition of Bacterial and Host-Derived H2S Production for the Therapeutic Enhancement of Anti-Bacterial Host Defense$193,750
R21 · FY2018 · AI
Therapeutic Repurposing of Benserazide for Colon Cancer$38,750
R21 · FY2018 · TR · contact PI
Therapeutic Repurposing of Benserazide for Colon Cancer$310,000
R21 · FY2017 · TR · contact PI
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy$300,000
R41 · FY2017 · CA · contact PI
Role of Hydrogen Sulfide in Colorectal Tumors$299,150
R01 · FY2017 · CA · contact PI
Regulation of cellular bioenergetics by hydrogen sulfide$294,500
R01 · FY2017 · GM · contact PI
Inhibition of Bacterial and Host-Derived H2S Production for the Therapeutic Enhancement of Anti-Bacterial Host Defense$232,500
R21 · FY2017 · AI
Project 8: Oxandrolone's mode of action in burns: role of steroid receptors and H2S pathways$131,118
P50 · FY2017 · GM · contact PI
Role of Hydrogen Sulfide in Colorectal Tumors$312,633
R01 · FY2016 · CA · contact PI
Regulation of cellular bioenergetics by hydrogen sulfide$294,500
R01 · FY2016 · GM · contact PI
Therapeutic Repurposing of Benserazide for Colon Cancer$271,250
R21 · FY2016 · TR · contact PI
Role of Hydrogen Sulfide in Colorectal Tumors$302,183
R01 · FY2015 · CA · contact PI
Regulation of cellular bioenergetics by hydrogen sulfide$294,500
R01 · FY2015 · GM · contact PI
Role of Hydrogen Sulfide in Colorectal Tumors$312,431
R01 · FY2014 · CA · contact PI
Regulation of cellular bioenergetics by hydrogen sulfide$293,867
R01 · FY2014 · GM · contact PI
PARS and peroxynitrite induced cell death$308,269
R01 · FY2009 · GM · contact PI
PARS and peroxynitrite induced cell death$313,306
R01 · FY2008 · GM · contact PI
PARS and peroxynitrite induced cell death$313,306
R01 · FY2007 · GM · contact PI
PARS and peroxynitrite induced cell death$322,663
R01 · FY2006 · GM · contact PI
Mechanisms of cardiovascular dysfunction in diabetes$349,875
R01 · FY2005 · HL
Myicardial injury: role of poly (ADP-ribose) synthetase$262,500
R01 · FY2005 · HL
Mechanisms of cardiovascular dysfunction in diabetes$418,140
R01 · FY2004 · HL
Myicardial injury: role of poly (ADP-ribose) synthetase$262,500
R01 · FY2004 · HL
Poly(ADP-ribose) synthetase inhibition and diabetes$199,825
R43 · FY2004 · DK
Novel antioxidants for periodontal disease$961,860
R44 · FY2003 · DE
Peroxynitrate neutralizing agents for stroke therapy$951,125
R44 · FY2003 · NS
Ultrapotent PARS inhibitor for CNS trauma$791,155
R44 · FY2003 · NS
Adenosine-3 agonists for the suppression of arthritis$581,080
R44 · FY2003 · AR
Mechanisms of cardiovascular dysfunction in diabetes$411,660
R01 · FY2003 · HL
Myicardial injury: role of poly (ADP-ribose) synthetase$262,500
R01 · FY2003 · HL
Doxorubicin cardiotoxicity:protection by peroxynitrite$174,806
R43 · FY2003 · CA
Adenosine-3 agonists for the suppression of arthritis$730,027
R44 · FY2002 · AR
Peroxynitrate neutralizing agents for stroke therapy$728,754
R44 · FY2002 · NS
Ultrapotent PARS inhibitor for CNS trauma$686,997
R44 · FY2002 · NS
Mechanisms of cardiovascular dysfunction in diabetes$405,428
R01 · FY2002 · HL
Myicardial injury: role of poly (ADP-ribose) synthetase$287,500
R01 · FY2002 · HL
POLY (ADP RIBOSE) SYNTHETASE AND PEROXYNITRITE INDUCED C$226,673
R01 · FY2002 · GM
Doxorubicin cardiotoxicity:protection by peroxynitrite$58,937
R43 · FY2002 · CA
PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK$876,780
R44 · FY2001 · GM
POLY (ADP RIBOSE) SYNTHETASE AND PEROXYNITRITE INDUCED C$220,155
R01 · FY2001 · GM
(ADP-ribose) synthetase inhibitor for multiple sclerosis$215,515
R43 · FY2001 · NS
POLY ADP RIBOSYLTRANSFERASE IN HEMORRHAGIC SHOCK$104,619
R29 · FY2001 · GM
POLY (ADP RIBOSE) SYNTHETASE AND PEROXYNITRITE INDUCED C$213,829
R01 · FY2000 · GM
POLY (ADP-RIBOSE) SYNTHETASE AND REPERFUSION INJURY$209,012
R01 · FY2000 · HL
POLY RIBOSE SYNTHETASE &ENDOTHELIAL DYSFUNCTION IN IDDM$104,277
R21 · FY2000 · HL
POLY ADP RIBOSYLTRANSFERASE IN HEMORRHAGIC SHOCK$100,926
R29 · FY2000 · GM